2019 JSH指南:乙型肝炎病毒感染的管理

2020-04-28 日本肝脏学会 Hepatol Res. 2020 Apr 28.

日本肝脏学会(JSH)第1版乙型肝炎病毒感染管理指南于2013年发布,此后随着新药的不断上市,指南也随之不断更新。本文是2019版乙型肝炎病毒感染的管理指南的英文版,主要内容涉及核苷酸类似物富马酸替诺

中文标题:

2019 JSH指南:乙型肝炎病毒感染的管理

英文标题:

JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update.

发布机构:

日本肝脏学会

发布日期:

2020-04-28

简要介绍:

日本肝脏学会(JSH)第1版乙型肝炎病毒感染管理指南于2013年发布,此后随着新药的不断上市,指南也随之不断更新。本文是2019版乙型肝炎病毒感染的管理指南的英文版,主要内容涉及核苷酸类似物富马酸替诺福韦和替诺福韦艾拉酚胺,耐药HBV的管理建议并更新HBV在激活的相关内容。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2019 JSH指南:乙型肝炎病毒感染的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3f9431c00190118e, title=2019 JSH指南:乙型肝炎病毒感染的管理, enTitle=JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update., guiderFrom=Hepatol Res. 2020 Apr 28., authorId=0, author=, summary=日本肝脏学会(JSH)第1版乙型肝炎病毒感染管理指南于2013年发布,此后随着新药的不断上市,指南也随之不断更新。本文是2019版乙型肝炎病毒感染的管理指南的英文版,主要内容涉及核苷酸类似物富马酸替诺, cover=https://img.medsci.cn/202058/1588951546435_2020535.jpg, journalId=0, articlesId=null, associationId=813, associationName=日本肝脏学会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Apr 28 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>日本肝脏学会(JSH)第1版乙型肝炎病毒感染管理指南于2013年发布,此后随着新药的不断上市,指南也随之不断更新。本文是2019版乙型肝炎病毒感染的管理指南的英文版,主要内容涉及核苷酸类似物富马酸替诺福韦和替诺福韦艾拉酚胺,耐药HBV的管理建议并更新HBV在激活的相关内容。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=61, tagName=乙型肝炎)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=61, guiderKeyword=乙型肝炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4176, appHits=410, showAppHits=38, pcHits=1145, showPcHits=3948, likes=2, shares=15, comments=5, approvalStatus=1, publishedTime=Fri May 08 23:57:40 CST 2020, publishedTimeString=2020-04-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri May 08 23:25:58 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 18:35:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2019 JSH指南:乙型肝炎病毒感染的管理.pdf)])
2019 JSH指南:乙型肝炎病毒感染的管理.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=966895, encodeId=f9539668951e, content=很高的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b91d2477323, createdName=1244e4c1m80暂无昵称, createdTime=Wed May 19 15:07:01 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943897, encodeId=ed0b94389e83, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210328/d1c2a77350ef4b7b8dd3973786c5553f/8505b172b90c4ec7898e5052a1252dad.jpg, createdBy=7a085451034, createdName=ms5000001613715131, createdTime=Sat Feb 27 09:44:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902980, encodeId=5ab29029803c, content=更新快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=348c5438885, createdName=ms8000000830541621, createdTime=Sat Nov 28 06:55:36 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812856, encodeId=9d4881285679, content=更新真的是快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/ibz2HQeVQM6BfkEWaWQnF5wn92jyroX7o8zcXA5JRbIfDHk4I39OsU1PhZKnvPhEN6sk3J8TenMibxGL68HMfTew/132, createdBy=92555321953, createdName=anne1023, createdTime=Mon Aug 24 23:58:17 CST 2020, time=2020-08-24, status=1, ipAttribution=)]
    2021-05-19 1244e4c1m80暂无昵称

    很高的文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=966895, encodeId=f9539668951e, content=很高的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b91d2477323, createdName=1244e4c1m80暂无昵称, createdTime=Wed May 19 15:07:01 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943897, encodeId=ed0b94389e83, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210328/d1c2a77350ef4b7b8dd3973786c5553f/8505b172b90c4ec7898e5052a1252dad.jpg, createdBy=7a085451034, createdName=ms5000001613715131, createdTime=Sat Feb 27 09:44:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902980, encodeId=5ab29029803c, content=更新快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=348c5438885, createdName=ms8000000830541621, createdTime=Sat Nov 28 06:55:36 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812856, encodeId=9d4881285679, content=更新真的是快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/ibz2HQeVQM6BfkEWaWQnF5wn92jyroX7o8zcXA5JRbIfDHk4I39OsU1PhZKnvPhEN6sk3J8TenMibxGL68HMfTew/132, createdBy=92555321953, createdName=anne1023, createdTime=Mon Aug 24 23:58:17 CST 2020, time=2020-08-24, status=1, ipAttribution=)]
    2021-02-27 ms5000001613715131

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=966895, encodeId=f9539668951e, content=很高的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b91d2477323, createdName=1244e4c1m80暂无昵称, createdTime=Wed May 19 15:07:01 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943897, encodeId=ed0b94389e83, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210328/d1c2a77350ef4b7b8dd3973786c5553f/8505b172b90c4ec7898e5052a1252dad.jpg, createdBy=7a085451034, createdName=ms5000001613715131, createdTime=Sat Feb 27 09:44:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902980, encodeId=5ab29029803c, content=更新快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=348c5438885, createdName=ms8000000830541621, createdTime=Sat Nov 28 06:55:36 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812856, encodeId=9d4881285679, content=更新真的是快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/ibz2HQeVQM6BfkEWaWQnF5wn92jyroX7o8zcXA5JRbIfDHk4I39OsU1PhZKnvPhEN6sk3J8TenMibxGL68HMfTew/132, createdBy=92555321953, createdName=anne1023, createdTime=Mon Aug 24 23:58:17 CST 2020, time=2020-08-24, status=1, ipAttribution=)]
    2020-11-28 ms8000000830541621

    更新快

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=966895, encodeId=f9539668951e, content=很高的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b91d2477323, createdName=1244e4c1m80暂无昵称, createdTime=Wed May 19 15:07:01 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943897, encodeId=ed0b94389e83, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210328/d1c2a77350ef4b7b8dd3973786c5553f/8505b172b90c4ec7898e5052a1252dad.jpg, createdBy=7a085451034, createdName=ms5000001613715131, createdTime=Sat Feb 27 09:44:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902980, encodeId=5ab29029803c, content=更新快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=348c5438885, createdName=ms8000000830541621, createdTime=Sat Nov 28 06:55:36 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812856, encodeId=9d4881285679, content=更新真的是快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/ibz2HQeVQM6BfkEWaWQnF5wn92jyroX7o8zcXA5JRbIfDHk4I39OsU1PhZKnvPhEN6sk3J8TenMibxGL68HMfTew/132, createdBy=92555321953, createdName=anne1023, createdTime=Mon Aug 24 23:58:17 CST 2020, time=2020-08-24, status=1, ipAttribution=)]
    2020-08-24 anne1023

    更新真的是快

    0

拓展阅读

2010 慢性乙型肝炎抗病毒治疗专家共识

慢性乙型肝炎抗病毒治疗专家委员会 · 2010-02-01

慢性乙型肝炎特殊患者抗病毒专家共识(2010)

慢性乙型肝炎特殊患者抗病毒治疗专家委员会 · 2010-02-01

2010 慢性乙型肝炎特殊患者抗病毒治疗专家共识

中国肝病科相关专家小组(统称) · 2010-02-28

乙型肝炎病毒、丙型肝炎病毒和/或人类免疫缺陷病毒感染医务工作者治疗指南(2010)

美国医疗保健流行病学学会(SHEA,Society for Healthcare Epidemiology of America) · 2010-03-01

2010 干扰素治疗慢性乙型肝炎专家建议

中国肝病科相关专家小组(统称) · 2010-04-01